Beam Therapeutics's book value per share for the quarter that ended in Dec. 2024 was $8.77.
During the past 12 months, Beam Therapeutics's average Book Value Per Share Growth Rate was -27.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -10.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Beam Therapeutics was 41.00% per year. The lowest was -10.10% per year. And the median was 15.45% per year.
Beam Therapeutics's current price is $19.82. Its book value per share for the quarter that ended in Dec. 2024 was $8.77. Hence, today's PB Ratio of Beam Therapeutics is 2.26.
During the past 8 years, the highest P/B Ratio of Beam Therapeutics was 7.44. The lowest was 1.74. And the median was 3.01.
Beam Therapeutics Book Value per Share Historical Data
The historical data trend for Beam Therapeutics's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Beam Therapeutics's Book Value per Share
For the Biotechnology subindustry, Beam Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beam Therapeutics's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beam Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Beam Therapeutics's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Beam Therapeutics (NAS:BEAM) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Beam Therapeutics Book Value per Share Related Terms
Thank you for viewing the detailed overview of Beam Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BEAM has been successfully added to your 